AGIO
Price
$22.30
Change
-$23.19 (-50.98%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.65B
85 days until earnings call
Intraday BUY SELL Signals
RIGL
Price
$41.61
Change
-$4.61 (-9.97%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
838.96M
Intraday BUY SELL Signals
Interact to see
Advertisement

AGIO vs RIGL

Header iconAGIO vs RIGL Comparison
Open Charts AGIO vs RIGLBanner chart's image
Agios Pharmaceuticals
Price$22.30
Change-$23.19 (-50.98%)
Volume$288.2K
Capitalization2.65B
Rigel Pharmaceuticals
Price$41.61
Change-$4.61 (-9.97%)
Volume$9.09K
Capitalization838.96M
AGIO vs RIGL Comparison Chart in %
AGIO
Daily Signal:
Gain/Loss:
RIGL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AGIO vs. RIGL commentary
Nov 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Hold and RIGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 19, 2025
Stock price -- (AGIO: $45.49 vs. RIGL: $46.22)
Brand notoriety: AGIO and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 99% vs. RIGL: 148%
Market capitalization -- AGIO: $2.65B vs. RIGL: $838.96M
AGIO [@Biotechnology] is valued at $2.65B. RIGL’s [@Biotechnology] market capitalization is $838.96M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 1 green FA rating(s).

  • AGIO’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 1 green, 4 red.
According to our system of comparison, AGIO is a better buy in the long-term than RIGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 5 TA indicator(s) are bullish while RIGL’s TA Score has 6 bullish TA indicator(s).

  • AGIO’s TA Score: 5 bullish, 3 bearish.
  • RIGL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both AGIO and RIGL are a good buy in the short-term.

Price Growth

AGIO (@Biotechnology) experienced а +3.72% price change this week, while RIGL (@Biotechnology) price change was +21.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

AGIO is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($2.65B) has a higher market cap than RIGL($839M). RIGL has higher P/E ratio than AGIO: RIGL (7.47) vs AGIO (3.82). RIGL YTD gains are higher at: 174.792 vs. AGIO (38.436). RIGL has higher annual earnings (EBITDA): 109M vs. AGIO (-470.31M). AGIO has more cash in the bank: 953M vs. RIGL (108M). AGIO has less debt than RIGL: AGIO (44.5M) vs RIGL (61M). RIGL has higher revenues than AGIO: RIGL (268M) vs AGIO (44.8M).
AGIORIGLAGIO / RIGL
Capitalization2.65B839M316%
EBITDA-470.31M109M-431%
Gain YTD38.436174.79222%
P/E Ratio3.827.4751%
Revenue44.8M268M17%
Total Cash953M108M882%
Total Debt44.5M61M73%
FUNDAMENTALS RATINGS
AGIO vs RIGL: Fundamental Ratings
AGIO
RIGL
OUTLOOK RATING
1..100
2222
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
8666
SMR RATING
1..100
958
PRICE GROWTH RATING
1..100
4336
P/E GROWTH RATING
1..100
41100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (45) in the Biotechnology industry is in the same range as RIGL (59). This means that AGIO’s stock grew similarly to RIGL’s over the last 12 months.

RIGL's Profit vs Risk Rating (66) in the Biotechnology industry is in the same range as AGIO (86). This means that RIGL’s stock grew similarly to AGIO’s over the last 12 months.

RIGL's SMR Rating (8) in the Biotechnology industry is significantly better than the same rating for AGIO (95). This means that RIGL’s stock grew significantly faster than AGIO’s over the last 12 months.

RIGL's Price Growth Rating (36) in the Biotechnology industry is in the same range as AGIO (43). This means that RIGL’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's P/E Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for RIGL (100). This means that AGIO’s stock grew somewhat faster than RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIORIGL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
74%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signal:
Gain/Loss:
RIGL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANJIX24.77N/A
N/A
Virtus NFJ International Value Inst
SNXFX14.35N/A
N/A
Schwab 1000 Index®
CVLOX13.72-0.08
-0.58%
Calamos Global Opportunities A
LGMNX26.72-0.19
-0.71%
Loomis Sayles Global Allocation N
COSTX12.96-0.14
-1.07%
Columbia Overseas Core Institutional 2